CN101502572B - Auxiliary Chinese and western medicinal composition for treating hepatitis - Google Patents
Auxiliary Chinese and western medicinal composition for treating hepatitis Download PDFInfo
- Publication number
- CN101502572B CN101502572B CN2009100795864A CN200910079586A CN101502572B CN 101502572 B CN101502572 B CN 101502572B CN 2009100795864 A CN2009100795864 A CN 2009100795864A CN 200910079586 A CN200910079586 A CN 200910079586A CN 101502572 B CN101502572 B CN 101502572B
- Authority
- CN
- China
- Prior art keywords
- hepatitis
- carapax
- radix
- chinese medicine
- plastrum testudinis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention discloses a composition of western medicine and traditional Chinese medicine for adjuvant therapy of the hepatitis, and an application of the composition in the prepration of drugs for adjuvant therapy of the hepatitis. The composition consists of bifendate and a traditional Chinese medicine extract by the weight ratio of 1: 110, the western medicine and the traditional Chinese medicine are synergetic to play the effects, so as to achieve the purpose of adjuvant therapy of the hepatitis.
Description
Invention field
The present invention relates to the Pharmaceutical composition formed by bifendate and Chinese medicine extract, and the purposes of said composition in the medicine of preparation adjuvant treating hepatitis.
Background technology
Hepatitis has multiple sorting technique clinically, classifies as (1) nosetiology: viral hepatitis can be divided into five types is first, second, third, fourth, penta.(2) clinical classification can be divided into following a few type: 1. acute anicteric hepatitis, this is a modal type in the viral hepatitis, see with B-mode, third type, hepatitis D more, general this type of hepatitis clinical symptoms is less, and transaminase's elevated levels is lower, and Histological change is light, mortality rate is lower, but the course of disease can be delayed the long period, and " three is slow " characteristics are arranged, and morbidity is slow, recovery is slow, delay also slow (referring to the long meaning slowly); 2. acute icterohepatitis is less relatively compared with anicteric hepatitis, and the state of an illness is a self limiting often, and how good prognosis is, but minority can develop into hepatitis gravis; 3. chronic hepatitis: relevant experts in 1994 propose the name and the suggestion of chronic hepatitis again, with the cause of disease is the diagnosis name that chronic hepatitis is determined on the basis, simultaneously ordered grade scale, formulated standard by stages according to degree of hepatic fibrosis again according to the downright bad order of severity of hepatitis inflammation; 4. hepatitis gravis can be divided into acute heavy type, severe subacute and chronic heavy type again; 5. cholestatic hepatitis.
Wherein hepatitis B is caused by hepatitis B virus, serves as main a kind of infectious disease that also can cause multiple organ injury with the liver inflammatory lesion.China is the most popular country of hepatitis B, reaches more than 35% some local crowd infection rate, and be the most serious infectious disease of current harm people ' s health.According to investigations, China's hepatitis B patient is about 2,700 ten thousand, and annual New Development patient about 9,000,000.
The hepatitis B clinical manifestation is various, easily develops into chronic hepatitis and liver cirrhosis, and a few peoples finally develop into hepatocarcinoma.Hepatic fibrosis is the total pathological change of many chronic hepatopathy evolutions, and the damage of chronic, persistence is the prerequisite that hepatic fibrosis forms.Cause the factor of hepatic injury a lot,, hepatitis B, liver cirrhosis, take some drugs for a long time and can cause acute and chronic liver injury generally because of factors such as medicine, a large amount of ethanol, allergy cause acute liver damage.By reducing detrimental effect to liver function, can adjuvant treating hepatitis.
The medicine that is used for the treatment of the acute and chronic hepatic injury at present, commonly used have bifendate, a diammonium glycyrrhizinate etc.These chemicalses generally have certain side effect, and cause that therapeutic effect at a specified future date is poor, problem such as Strain produces after drug resistance phenomenon, the drug withdrawal relapse rate height.
The curative effect of Chinese medicine hepatitis B is proved by a large amount of clinical trials.Chinese medicine all can be brought into play curative effect preferably at aspects such as antiviral, adjusting immunity of organisms, protection hepatocyte.But Chinese medicine preparation ubiquity onset at present is slow, needs problems such as life-time service.
Therefore, Western medicine and Chinese Medicine and Clavicular need be got up, i.e. synergism is played in Chinese medicine and western medicine combination, solves the problem that above-mentioned Western medicine and Chinese medicine exist in auxiliary treatment all kinds hepatitis separately, produces synergistic therapeutic effect simultaneously.
Summary of the invention
One object of the present invention is to provide the Pharmaceutical composition of being made up of bifendate and a kind of Chinese medicine extract, and wherein the Chinese medicine extract of said composition prepares according to the method for embodiment among the Chinese patent CN1233388C, and is as follows:
Get raw material by following weight proportion: Radix Cudraniae 82g, Radix berchemiae lineatae 82g, Rhizoma Polygoni Cuspidati 41g, Herba Desmodii Styracifolii 82g, Cornu Bubali 82g, Herb Gynostemmae Pentaphylli 41g, Radix Astragali 41g, Carapax Et Plastrum Testudinis 8g;
More than eight flavors, get Carapax Et Plastrum Testudinis and pulverize, cross sieve No. 1; Other Cornu Bovis seu Bubali pound flakiness of fetching water, Carapax Et Plastrum Testudinis powder and Cornu Bubali slice decoct with water three times, and each 5 hours, replenish the moisture that boils off in the decoction process at any time, collecting decoction filters, and filtrate is concentrated into relative density 1.30-1.35 (80 ℃); Six-elements such as all the other Radix Cudraniaes, Radix berchemiae lineatae decoct with water each 2 hours three times, collecting decoction, filter, filtrate is concentrated into relative density 1.15～1.18 (80 ℃), and it is 70% that adding ethanol makes medicinal liquid contain the alcohol amount, left standstill 12 hours, the leaching supernatant reclaims ethanol, adds Carapax Et Plastrum Testudinis and Cornu Bubali concentrated solution, continue to concentrate, be dried to dry extract.
One object of the present invention is to provide the purposes of above-mentioned Pharmaceutical composition in preparation auxiliary treatment all kinds hepatitis medicament.
This Chinese medicine the water extracted immersing paste is called " the described Chinese medicine extract of this paper (or above) " hereinafter.
Above-mentioned composition and mixing acceptable accessories can be made acceptable forms clinically, as tablet, capsule, granule, oral liquid, subcutaneous administration preparation, suppository etc.
Pharmacological research
The main pharmacodynamics of Pharmaceutical composition of the present invention studies confirm that it has strong transaminase lowering effect, i.e. function for protecting liver and reducing enzyme activity.
Edit with reference to Zhang Juntian, " modern pharmacology test method " (volume two), combined publication society of China Concord Medical Science University of Beijing Medical University, the 1397-1398 page or leaf, disclosed method in " first segment chmice acute chemical liver injury model ", set up the acute chemical liver injury model of mouse carbon tetrachloride, carry out the pharmacodynamics test of Pharmaceutical composition anti-liver injury of the present invention.
The test grouping:
1 normal control group: animal does not do any processing, and normal physiological saline is irritated stomach;
2 model control group: after the animal model modeling success, normal physiological saline is irritated stomach;
2 pure Chinese drug-treated group: the water extracted immersing paste 1.10g/kg body weight as indicated above
3 bifendate groups: the 10mg/kg body weight is irritated stomach
4 compositions groups: 10mg/kg body weight bifendate+the water extracted immersing paste 1.10g/kg body weight mentioned above is irritated stomach.
Following table has shown the influence of each group to Mouse Liver function leading indicator GOT, GPT.
| Group | Number of animals | GOT (active unit) | GPT (active unit) |
| The normal control group | 10 | 21.92±17.85 | 45.31±16.35 |
| Model control group | 10 | 250.76±76.58 | 306.25±59.47 |
| Pure Chinese drug-treated group | 10 | 171.22±55.32 | 228.41±49.21 |
| The bifendate group | 10 | 98.78±41.52 | 189.65±23.85 |
| The compositions group | 10 | 89.01±23.98 | 97.23±38.23 |
This table shows that all there is significant difference (P＜0.05) in each group (pure Chinese drug-treated group, bifendate group, compositions group) of treatment with model control group, and all there are significant difference (P＜0.05) in compositions group and pure Chinese drug-treated group, compositions group and bifendate group.Show that there are cooperative effect in bifendate and described Chinese medicinal components in the compositions group.
The pharmaceutics test
Can produce the tablet that contains following component in a conventional manner:
Component
The Mg/ sheet
Pharmaceutical composition 200-1000 of the present invention
Corn starch 125.0
Pulvis Talci 75.0
Magnesium stearate 1.0
Wherein compositions is made up of with weight ratio bifendate and Chinese medicine extract mentioned above at 1: 110.
Can produce the capsule that contains following component in a conventional manner:
Component
The Mg/ sheet
Pharmaceutical composition 200-1000 of the present invention
Lactose 10.0
Corn starch 20.0
Talcum 5.0
Wherein compositions is made up of with weight ratio bifendate and Chinese medicine extract mentioned above at 1: 110.
Claims (2)
1. the liver protecting and ALT lowering Pharmaceutical composition, it is made up of with weight ratio bifendate and Chinese medicine extract at 1: 110, and described Chinese medicine extract is by following method preparation:
Get raw material by following weight proportion: Radix Cudraniae 82g, Radix berchemiae lineatae 82g, Rhizoma Polygoni Cuspidati 41g, Herba Desmodii Styracifolii 82g, Cornu Bubali 82g, Herb Gynostemmae Pentaphylli 41g, Radix Astragali 41g, Carapax Et Plastrum Testudinis 8g;
More than eight flavors, get Carapax Et Plastrum Testudinis and pulverize, cross sieve No. 1; Other Cornu Bovis seu Bubali pound flakiness of fetching water, Carapax Et Plastrum Testudinis powder and Cornu Bubali slice decoct with water three times, and each 5 hours, replenish the moisture that boils off in the decoction process at any time, collecting decoction filters, and filtrate is concentrated into relative density 1.30-1.35,80 ℃; Six-elements such as all the other Radix Cudraniaes, Radix berchemiae lineatae decoct with water each 2 hours three times, collecting decoction filters, and filtrate is concentrated into relative density 1.15～1.18,80 ℃, it is 70% that adding ethanol makes medicinal liquid contain the alcohol amount, leaves standstill the leaching supernatant 12 hours, reclaim ethanol, add Carapax Et Plastrum Testudinis and Cornu Bubali concentrated solution, continue to concentrate, be dried to dry extract.
2. the purposes of compositions as claimed in claim 1 in the medicine of the auxiliary the liver protecting and ALT lowering of preparation.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2009100795864A CN101502572B (en) | 2009-03-11 | 2009-03-11 | Auxiliary Chinese and western medicinal composition for treating hepatitis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2009100795864A CN101502572B (en) | 2009-03-11 | 2009-03-11 | Auxiliary Chinese and western medicinal composition for treating hepatitis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101502572A CN101502572A (en) | 2009-08-12 |
| CN101502572B true CN101502572B (en) | 2010-10-13 |
Family
ID=40975034
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2009100795864A Expired - Fee Related CN101502572B (en) | 2009-03-11 | 2009-03-11 | Auxiliary Chinese and western medicinal composition for treating hepatitis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101502572B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101862380A (en) * | 2010-02-10 | 2010-10-20 | 李瑞菊 | Medicinal composition |
| CN101856402B (en) * | 2010-06-17 | 2011-09-14 | 宁波市鄞州昌达生物科技有限公司 | Medicament composition for adjuvant treating hepatitis |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1519018A (en) * | 2003-09-02 | 2004-08-11 | 梁珍惠 | Combination of medicine for treating hepatitis |
-
2009
- 2009-03-11 CN CN2009100795864A patent/CN101502572B/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1519018A (en) * | 2003-09-02 | 2004-08-11 | 梁珍惠 | Combination of medicine for treating hepatitis |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101502572A (en) | 2009-08-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100444857C (en) | Medicine for auxiliary treating hepatitis | |
| CN101810694B (en) | Traditional Chinese medicine and western medicine composition for adjunctive therapy of hepatitis | |
| CN101502572B (en) | Auxiliary Chinese and western medicinal composition for treating hepatitis | |
| CN100448462C (en) | Synergistic medicinal composition containing diammonium glycyrrhizinate and Chinese medicine | |
| CN101502551B (en) | Synergistic composition containing bifendate | |
| CN100367978C (en) | Synergistic medicinal composition | |
| CN100356960C (en) | Synergistic medicinal composition for treating hepatitis | |
| CN101856402B (en) | Medicament composition for adjuvant treating hepatitis | |
| CN101716239B (en) | Medical composition containing oleanolic acid | |
| CN101837036B (en) | Synergetic medicinal composition | |
| CN100363035C (en) | Cooperative medicinal composition comprising biphenyldicarboxylate and traditional Chinese medicine extract | |
| CN100363045C (en) | Traditional Chinese medicine and western medicine compositions comprising biphenyldicarboxylate for treating hepatitis accessorily | |
| CN100450498C (en) | Accessory medicinal composition for treating hepatitis | |
| CN100421697C (en) | Synergistic medicinal composition containing diammonium glycyrrhizinate and Chinese medicine | |
| CN100393337C (en) | Synergistic medicinal composition | |
| CN100353981C (en) | Medicine for auxiliary treating hepatitis | |
| CN100448459C (en) | Synergistic medicine composition for treating hepatitis | |
| CN100363041C (en) | Traditional Chinese medicine and western medicine cooperative compositions comprising biphenyldicarboxylate | |
| CN101810755B (en) | Synergism traditional Chinese medicine and western medicine composition containing oleanolic acid | |
| CN101721451B (en) | Synergistic medicinal composition | |
| CN100353978C (en) | Synergistic medicinal composition containing tiopronin and Chinese medicine extract | |
| CN101843820B (en) | Glucuronolactone-containing medicament for protecting liver and lowering transaminase | |
| CN100434096C (en) | Drug for treating hepatitis comprising biphenyldicarboxylate | |
| CN100421686C (en) | Chinese-western medicine composition for treating hepatitis | |
| CN100444866C (en) | Synergistic medicinal composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| ASS | Succession or assignment of patent right |
Owner name: ZHANG YAN Free format text: FORMER OWNER: RAO HUI Effective date: 20100730 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| C53 | Correction of patent for invention or patent application | ||
| CB03 | Change of inventor or designer information |
Inventor after: Zhang Yan Inventor before: Rao Hui |
|
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 100730 2028, ZIFENG BUILDING, NO.1, DAYABAO LANE, DONGCHENG DISTRICT, BEIJING CITY TO: 315105 SIGANG RESIDENTIAL QUARTER, XIAYING STREET, YINZHOU DISTRICT, NINGBO CITY, ZHEJIANG PROVINCE Free format text: CORRECT: INVENTOR; FROM: RAO HUI TO: ZHANG YAN |
|
| TA01 | Transfer of patent application right |
Effective date of registration: 20100730 Address after: 315105, Zhejiang, Ningbo, Yinzhou District should be down street Si Hong Kong District Applicant after: Zhang Yan Address before: Zifeng Building 1 No. 100730 Beijing Dongcheng District Yabao alley 2028 Applicant before: Rao Hui |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20101013 Termination date: 20110311 |